Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04925375 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease

Study acronym: ABCVILD
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Jul 2026 to Jul 2028v17
  2. Primary and study completion dates: Jul 2025 to Jul 2026 Site contacts updated at 1 of 6 sitesv16 Show 1 more changeShow less
    • Site contacts updated at 1 of 6 sites
  3. Eligibility criteria expanded, about 86 words Study description expanded, about 80 wordsv15 Show 1 more changeShow less
    • Study description expanded, about 80 words

    See this version in full on ClinicalTrials.gov ↗

  4. Site contacts updated at 1 of 6 sitesv14
  5. Site contacts updated at 1 of 6 sitesv13
Show 11 earlier versionsHide 11 earlier versions
  1. Study sites: 5 to 6v12
  2. Study sites: 4 to 5v11
  3. Enrollment target: 60 to 38 Eligibility criteria expanded, about 4 words · Study description expanded, about 1 wordv10 Show 2 more changesShow less
    • Eligibility criteria expanded, about 4 words
    • Study description expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  4. Study sites: 3 to 4v9
  5. Study sites: 2 to 3v8
  6. Study sites: 1 to 2v7
  7. Eligibility criteria expanded, about 51 wordsv6 See this version in full on ClinicalTrials.gov ↗
  8. Re-verified, no change to tracked fieldsv5
  9. Primary and study completion dates: Jun 2025 to Jul 2025 Start date changed from estimate of Jul 2021 to Jul 14, 2021v4 Show 1 more changeShow less
    • Start date changed from estimate of Jul 2021 to Jul 14, 2021
  10. Start date: Jun 2021 to Jul 2021v3
  11. Trial status: Not Yet Recruiting to Recruitingv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
There is no standard of care therapy for patients with granulomatous-lymphocytic interstitial lung disease (GLILD) seen in common variable immunodeficiency (CVID). Abatacept has recently looked promising for the treatment of patients with complex CVID. This study is a multi-site, phase II, randomized, blinded/placebo-controlled clinical trial in pediatric and adult subjects to determine the efficacy of abatacept compared to placebo for treatment of subjects with GLILD in the context of CVID. Funding Source - FDA OOPD
Trial Details
NCT Number NCT04925375
Lead Sponsor Children's Hospital Medical Center, Cincinnati
Collaborators: Bristol-Myers Squibb
Conditions Interstitial Lung Disease, Common Variable Immunodeficiency
Enrollment 38 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov